BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety

Esraa Alkhalil; Bashar Jarad; Tala Saleh; Wafaa Aldarwish; Dima Joujeh

doi:10.56782/pps.292

Published : 2025-02-05

Vol. 23 No. 1 (2025)

BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety

Esraa Alkhalil

Bashar Jarad

Tala Saleh

Wafaa Aldarwish

Dr. Dima Joujeh

DOI: https://doi.org/10.56782/pps.292

Abstract

The investigation into the Pfizer vaccine for the Coronavirus (COVID-19) is a vital area of study, especially given the ongoing global pandemic. The safety, efficacy, and overall credibility of the Pfizer vaccine remain contentious issues. This research seeks to deliver a thorough and unbiased examination of the vaccine's production process, its functional mechanism, and its immunogenic properties. It also presents the latest scientific findings concerning the vaccine's safety and efficacy based on recent clinical trials. The analysis is conducted with impartiality, ensuring that data and scientific outcomes are reported without prejudice.

BNT162b2 is a nucleoside-modified mRNA vaccine formulated with lipid nanoparticles, designed to encode the spike protein of SARS-CoV-2, which stimulates an immune response in those vaccinated. The Pfizer-BioNTech mRNA COVID-19 vaccine incorporates an advanced cap 1 analog, a specific 5′ UTR region derived from the human α-globin gene, and an optimized downstream Kozak consensus sequence. The mRNA sequence has been enhanced by introducing N1-methyl-Ψ, substituting all uridines, including those in stop codons. The 3′-UTR of the BNT162b2 mRNA includes sequences from the amino-terminal enhancer of split mRNA and mitochondrial 12S rRNA, alongside a 30-mer poly(A) tail and a 10-nucleotide linker, which together improve and extend protein expression.

As of May 30, 2024, the U.S. National Library of Medicine (Clinicaltrials.gov) lists 1,314 clinical trials globally related to COVID-19 mRNA vaccines, with 135 specifically focusing on BNT162b2, most of which are in Phase II and III. Numerous trials have confirmed the vaccine's effectiveness and safety, with no major adverse effects reported in the majority of studies. Access to reliable information on the Pfizer-BioNTech vaccine is vital for public awareness and informed vaccination decisions, emphasizing the importance of ongoing trials to update medical literature, especially as the vaccine is evaluated across various age groups and against new SARS-CoV-2 variants.

Keywords:

SARS-CoV-2, Nucleoside-modified mRNA, Immuno response Mechanism, Clinical trials

Similar Articles

Agnieszka Lembas, Andrzej Załęski, Tomasz Mikuła, Joanna Jabłońska, Szymon Barczak, Barbara Badura, Alicja Wiercińska-Drapało, Differences in the course of hepatocellular carcinoma depending on the DAA treatment , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)

<< < 3 4 5 6 7 8

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Alkhalil, E., Jarad, B., Saleh, T., Aldarwish, W., & Joujeh, D. (2025). BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety. Prospects in Pharmaceutical Sciences, 23(1), 31–46. https://doi.org/10.56782/pps.292

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

1. World Health Organization (March 2020). ‘’WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020”. Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. (accessed on 17-10-2024)

2. World Health Organization. WHO COVID-19 dashboard. “COVID-19 Global circulation.” Available online: https://data.who.int/dashboards/covid19. (accessed on 17-10-2024)

3. Trojánek, M.; Grebenyuk, V.; Herrmannová, K.; Nečas, T.; Gregorová, J.; Kucbel, M.; et al. Novel coronavirus (SARS-CoV-2) and COVID-19. Cas. Lek. Cesk. 2020, 159(2), 55-66. Available online: https://www.prolekare.cz/casopisy/casopis-lekaru-ceskych/2020-2-6/novy-koronavirus-sars-cov-2-a-onemocneni-covid-19-122272

4. Lamer, M.; Haagmans, B. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 2022, 20, 270-284. DOI: 10.1038/s41579-022-00713-0 DOI: https://doi.org/10.1038/s41579-022-00713-0

5. Wang, Y.; Grunewald, M.; Perlman, S. Coronaviruses: An Updated Overview of Their Replication and Pathogenesis. In: Coronaviruses. Methods Mol Bio,. Maier, H., Bickerton, E. (eds). Humana, New York, NY. 2020, vol 2203, 1-29. DOI: 10.1007/978-1-0716-0900-2_1 DOI: https://doi.org/10.1007/978-1-0716-0900-2_1

6. Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Ann. Rev. Virol. 2016, 3(1), 237-261. DOI: 10.1146/annurev-virology-110615-042301 DOI: https://doi.org/10.1146/annurev-virology-110615-042301

7. Sharma, B.; Ravindra, P. Immune responses to infection and covid-19 vaccines. Explor. Immunol. 2022, 2, 648-664. DOI: 10.37349/ei.2022.00074 DOI: https://doi.org/10.37349/ei.2022.00074

8. Farhud, D.; Zokaei, S. A Brief Overview of COVID-19 Vaccines. Iran. J. Public Health 2021, 50(7), 1-6. DOI: 10.18502/ijph.v50i7.6656 DOI: https://doi.org/10.18502/ijph.v50i7.6656

9. Chung, V.; Beiss, V.; Fiering, S.; Steinmetz, N. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS. Nano 2020, 14, 12522−12537. DOI: 10.1021/acsnano.0c07197 DOI: https://doi.org/10.1021/acsnano.0c07197

10. Schlake, T.; Thess, A.; Fotin-Mleczek, M.; Kallen, K. Developing mRNA-vaccine technologies. RNA. Biol. 2012, 9(11), 1319–1330. DOI: 10.4161/rna.22269 9 DOI: https://doi.org/10.4161/rna.22269

11. Szabó, G.; Mahiny, A.; Vlatkovic, I. COVID-19 mRNA vaccines: Platforms and current developments. Mol. Ther. 2022, 30(5), 1850-1868. DOI: 10.1016/j.ymthe.2022.02.016 DOI: https://doi.org/10.1016/j.ymthe.2022.02.016

12. Naqvia, A.; Fatimab, K.; Mohammada, T.; Fatimac, U.; Singhd, I.; Singhe, A.; et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. BBA Mol. Basis Dis. 2020, 1866 (10), Art. No: 165878. DOI: 10.1016/j.bbadis.2020.165878 DOI: https://doi.org/10.1016/j.bbadis.2020.165878

13. Young, M.; Crook, H.; Scott, J.; Edison, P. Covid-19: virology, variants, and vaccines. Bmj Med. 2022,1(1), Art. No: e000040. DOI: 10.1136/bmjmed-2021-000040 DOI: https://doi.org/10.1136/bmjmed-2021-000040

14. Masters, P. The molecular biology of coronaviruses. Adv. Virus Res. 2006, 66, 193–292. DOI: 10.1016%2FS0065-3527(06)66005-3. DOI: https://doi.org/10.1016/S0065-3527(06)66005-3

15. Jungreis, I.; Sealfon, R.; Kellis, M. SARS-CoV-2 gene content and COVID-19 mutation Impact by comparing 44 Sarbecovirus genomes. Nat. Commun. 2021,12, 1-20. DOI: 10.1038/s41467-021-22905- 7 DOI: https://doi.org/10.1038/s41467-021-22905-7

16. Ke, Z.; Oton, J.; Qu, K.; Cortese, M.; Zila, V.; McKeane, L.; et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 2020, 588, 498–502. DOI: 10.1038/s41586-020-2665-2 DOI: https://doi.org/10.1038/s41586-020-2665-2

17. Huang, Y.; Yang, C.; Xu, W.; Liu, S. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 2020, 41, 1141–1149. DOI: 10.1038/s41401-020-0485-4 DOI: https://doi.org/10.1038/s41401-020-0485-4

18. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020, 367(6485), 1444-1448. DOI: 10.1126/science.abb2762 DOI: https://doi.org/10.1126/science.abb2762

19. Abdulla, A.; Al-Bashir, S.; Alzoubi, H.; Al-Salih, N.; Aldamen, A.; Abdulazeez, A. The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups. Pathogens 2023, 12(2), Art. No: 329. DOI: 10.3390/pathogens12020329 . DOI: https://doi.org/10.3390/pathogens12020329

20. Szymczak, A.; Jędruchniewicz, N.; Torelli, A.; Kaczmarzyk-Radka, A.; Coluccio, R.; Kłak, M.; et al. Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples. J.Gen. Virol. 2021,102(11), Art. No: 001692. DOI: 10.1099/jgv.0.001692 DOI: https://doi.org/10.1099/jgv.0.001692

21. Primorac, D.; Vrdoljak, K.; Brlek, p.; Pavelic, E.; Molnar, V.; Matisˇic', V.; et al. Adaptive Immune Responses and Immunity to SARS-CoV-2. Front. Immunol. 2022, 13, Art. No: 848582. DOI: 10.3389/fimmu.2022.848582 DOI: https://doi.org/10.3389/fimmu.2022.848582

22. Manna, P.; Reddy, P. Healthy immunity on preventive medicine for combating covid-19. Nutrients 2022, 14(5), Art. No: 1004. DOI: 10.3390/nu14051004 DOI: https://doi.org/10.3390/nu14051004

23. Silva, M.; Ribeiro, L.; Lima, K.; Lirr, L. Adaptive immunity to SARS-CoV-2 infection: A systematic review. Front. Immunol. 2022, 13, Art. No: 1001198. DOI: 10.3389/fimmu.2022.1001198 DOI: https://doi.org/10.3389/fimmu.2022.1001198

24. Fenwick, C.; Croxatto, A.; Coste, A.; Pojer, F.; André, C.; Pellaton, C.; et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population Based Seroprevalence Studies. J. Virol. 2021, 95(3), e01828-20. DOI: 10.1128/jvi.01828-20 DOI: https://doi.org/10.1128/JVI.01828-20

25. Krammer, F. SARS-CoV-2 vaccines in development. Nature 2020, 586, 516-527. DOI: 10.1038/s41586-020-2798-3 DOI: https://doi.org/10.1038/s41586-020-2798-3

26. Gote, V.; Bolla, P.; Kommineni, N.; Butreddy, A.; Nukala, P.; Palakurthi, S. A Comprehensive Review of mRNA Vaccines. Int. J. Mol. Sci. 2023, 24, Art. No: 2700. DOI: 10.3390/ijms24032700 DOI: https://doi.org/10.3390/ijms24032700

27. Karam, M.; Daoud, G. mRNA vaccine: Past, present, future. AJPS 2022, 17(4), 491-522. DOI: 10.1016/j.ajps.2022.05.003 DOI: https://doi.org/10.1016/j.ajps.2022.05.003

28. Rosa, S.; Prazeres, M.; Azevedo, M.; Marques, P. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine 2021, 39(16), 2190–2200. DOI: 10.1016/j.vaccine.2021.03.038. DOI: https://doi.org/10.1016/j.vaccine.2021.03.038

29. Kwon, H.; Kim, M.; Seo, Y.; Moon, Y. S.; Lee, H. J.; Lee, K.; et al. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its application in regenerative medicine. Biomaterials 2018, 156, 172-193. DOI: 10.1016/j.biomaterials.2017.11.034 DOI: https://doi.org/10.1016/j.biomaterials.2017.11.034

30. Whitley, J.; Zwolinskiz, C.; Dwnis, C.; Maughan, M.; Hayles, L.; Clarke, D.; et al. Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Transl. Res. 2021, 242, 38-55. DOI: 10.1016/j.trsl.2021.11.009 DOI: https://doi.org/10.1016/j.trsl.2021.11.009

31. Henderson, J.; Ujita, A.; Hill, E.; Yousif-Rosales, S.; Smith, C.; Ko, N.; et al. Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap® Analog by In Vitro Transcription. Curr. Protoc. 2021, 1(2), Art. No: e39. DOI: 10.1002/cpz1.39 DOI: https://doi.org/10.1002/cpz1.39

32. Jalkanen, A.; Coleman, S.; Wilusz, J. Determinants and implications of mRNA poly(A) tail size – Dose this protein make my tail look big?. Semin. Cell Dev. Biol. 2014, 34, 24-32. DOI: 10.1016/j.semcdb.2014.05.018 DOI: https://doi.org/10.1016/j.semcdb.2014.05.018

33. Chaudhary, N.; Weissman, D.; Whitehead, K. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 2021, 20, 817–838. DOI: 10.1038/s41573-021-00283-5 DOI: https://doi.org/10.1038/s41573-021-00283-5

34. Thorn, C.; Sharma, D.; Combs, R.; Bhujbal, S.; Romine, J.; Zheng, X.; et al. The journey of a lifetime — development of Pfizer’s COVID-19 vaccine. Curr. Opin. Biotechnol. 2022, 78, Art. No: 102803. DOI: 10.1016/j.copbio.2022.102803 DOI: https://doi.org/10.1016/j.copbio.2022.102803

35. Tossberg, T.; Esmond, T.; Aune, T. A simplified method to produce mRNAs and functional proteins from synthetic double-stranded DNA templates. Biotechniques 2020, 69(4), 281–288. DOI: 10.2144/btn-2020-0037. DOI: https://doi.org/10.2144/btn-2020-0037

36. Mey, W.; Schrijver, P.; Autaers, D.; Pfitzer, L.; Fant, B.; Locy, H.; et al. A synthetic DNA template for fast manufacturing of versatile single epitope mRNA. Mol. Ther. Nucleic Acids 2022, 17(29), 943-954. DOI: 10.1016/j.omtn.2022.08.021 DOI: https://doi.org/10.1016/j.omtn.2022.08.021

37. Zhang, F.; Wang, W.; Wang, X.; Dong, H.; Chen, M.; Du, N. RT-IVT method allows multiplex real-time quantification of in vitro transcriptional mRNA production. Commun. Biol. 2023, 6, Art. No: 453. DOI: 10.1038/s42003-023-04830-1 DOI: https://doi.org/10.1038/s42003-023-04830-1

38. Kang, D.; Li, H.; Dong, Y. Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics Advanced Drug Delivery Reviews. Adv. Drug Deliv. Rev. 2023, 199, Art. No: 114961. DOI: 10.1016/j.addr.2023.114961 DOI: https://doi.org/10.1016/j.addr.2023.114961

39. Zhang, J.; Liu, Y.; Li, C.; Xiao, Q.; Zhang, D.; Chen, y.; et al. Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules. Pharmaceutics 2023, 15(9), Art. No: 2182. DOI: 10.3390/pharmaceutics15092182 DOI: https://doi.org/10.3390/pharmaceutics15092182

40. Wang, Y.; Kumari, M.; Chen, G.; Hong, M.; Yuanb, J.; Tsai, J.; Wu, H. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications. J. Biomed. Sci. 2023, 30(1), Art. No: 84. DOI: 10.1186/s12929-023-00977-5 DOI: https://doi.org/10.1186/s12929-023-00977-5

41. Wolf, J.; Dai, N.; Chan, S.; Ivan, R.; Jr. Selective Characterization of mRNA 5′ End-Capping by DNA ProbeDirected Enrichment with Site-Specific Endoribonucleases. ACS Pharmacol. Transl. Sci. 2023, 6(11), 1692-1702. DOI: 10.1021/acsptsci.3c00157. DOI: https://doi.org/10.1021/acsptsci.3c00157

42. Granados-Riveron, J.; and Aquino-Jarquin, G. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Biomed. Pharmacother. 2021, 142, Art. No: 111953. DOI: 10.1016/j.biopha.2021.111953 DOI: https://doi.org/10.1016/j.biopha.2021.111953

43. Nance, K.; Meier, J. L. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Cent. Sci. 2021, 7(5), 748-756. DOI: 10.1021/acscentsci.1c00197. DOI: https://doi.org/10.1021/acscentsci.1c00197

44. Xia, X. Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines. Vaccines (Basel) 2021, 9(7), Art. No: 734. DOI: 10.3390/vaccines9070734. DOI: https://doi.org/10.3390/vaccines9070734

45. World Health Organization (September 2020). "Messenger RNA encoding the full length SARS-CoV-2 spike glycoprotein" (DOC). (accessed on 17-10-2024)

46. Morais, P.; Adachi, H.; Yu, YT. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. Front. Cell Dev. Biol. 2021, 9, Art. No: 789427. DOI: 10.3389/fcell.2021.789427 DOI: https://doi.org/10.3389/fcell.2021.789427

47. Verbeke, R.; Lentacker, I.; Smedt, S.; Dewitte, H. The dawn of mRNA vaccines: The COVID-19 case. J. Control. Rel. 2021, 333, 511–520. DOI: 10.1016/j.jconrel.2021.03.0433 DOI: https://doi.org/10.1016/j.jconrel.2021.03.043

48. Lewis, L.; Badkar, A.; Cirelli, D.; Combs, R.; Lerch, T. The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists’ Perspective. J. Pharm. Sci. 2022, 112(3), 640-647. DOI: 10.1016/j.xphs.2022.09.014 DOI: https://doi.org/10.1016/j.xphs.2022.09.014

49. Kim, S.; Sekhon, S.; Shin, W.; Ahn, G.; Cho, B.; Ahn, J.; et al. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol. Cell Toxicol. 2022, 18(1), 1-8. DOI: 10.1007/s13273-021-00171-4 DOI: https://doi.org/10.1007/s13273-021-00171-4

50. Feng, X.; Su, Z.; Cheng, Y.; Ma, G.; Zhang, S. Messenger RNA chromatographic purification: advances and challenges. J. Chrom. 2023, 1707, Art. No: 464321. DOI: 10.1016/j.chroma.2023.464321 DOI: https://doi.org/10.1016/j.chroma.2023.464321

51. Kariko, K.; Muramatsu, H.; Ludwig, J.; Weissman, D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011, 39(21), Art. No: e142. DOI: 10.1093/nar/gkr695 DOI: https://doi.org/10.1093/nar/gkr695

52. Baronti, L.; Karlsson, H.; Marušič, M.; Petzold, K. A guide to large-scale RNA sample preparation. Anal. Bioanal. Chem. 2018, 410(14), 3239-3252. DOI: 10.1007/s00216-018-0943-8 DOI: https://doi.org/10.1007/s00216-018-0943-8

53. Wallace, R.; Rochfort, K. Ion-Exchange Chromatography: Basic Principles and Application. Methods Mol. Biol. 2023, 2699, 161-177. DOI: 10.1007/978-1-0716-3362-5_9 DOI: https://doi.org/10.1007/978-1-0716-3362-5_9

54. Grinsted, J.; Liddell, J.; Bouleghlimat, E.; Kwok, K.; Taylor, D.; Marques, M.; et al. Purification of therapeutic & prophylactic mRNA by affinity chromatography. Cell Gene Ther. Insights 2022, 8(2), 335–349. DOI: 10.18609/cgti.2022.049 DOI: https://doi.org/10.18609/cgti.2022.049

55. Mascellino, M.; Timoteo, F.; Angelis, M.; Oliva, A. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infect. Drug Resist. 2021, 14, 3459–3476. DOI: 10.2147/IDR.S315727 DOI: https://doi.org/10.2147/IDR.S315727

56. Hengelbrock, A.; Schmidt, A.; Strube, J. Formulation of Nucleic Acids by Encapsulation in Lipid Nanoparticles for Continuous Production of mRNA. Processes 2023, 11, Art. No: 1718. DOI: 10.3390/pr11061718 DOI: https://doi.org/10.3390/pr11061718

57. Park, J.; Lagniton, P.; Liu, Y.; Xu, R. mRNA vaccines for COVID-19: what, why and how. Int. J. Biol. Sci. 2021, 17, 1446-1460. DOI: 10.7150/ijbs.59233 DOI: https://doi.org/10.7150/ijbs.59233

58. Wilson, B.; Geetha, K. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J. Drug Deliv. Sci. Technol. 2022, 74, 2-7. DOI: 10.1016/j.jddst.2022.103553 DOI: https://doi.org/10.1016/j.jddst.2022.103553

59. Semple, S.; Leone, R. Barbose C, Tam Y, Lin P. Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics. Pharmaceutics 2022, 14(2), Art. No: 398. DOI: 10.3390/pharmaceutics14020398. DOI: https://doi.org/10.3390/pharmaceutics14020398

60. Chen, K.; Fan, N.; Huang, H.; Jiang, X.; Qin, S.; Wen, Xiao. W.; et al. mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids. Adv. Funct. Mater. 2022, 32(39), Art. No: 2204692. DOI: 10.1002/adfm.202204692 DOI: https://doi.org/10.1002/adfm.202204692

61. Lamb, Y. BNT162b2 mRNA COVID 19 Vaccine: First Approval. Drugs. 2021, 81(4), 495–501. DOI: 10.1007/s40265-021-01480-7 DOI: https://doi.org/10.1007/s40265-021-01480-7

62. Zeng, C.; Zhang, C.; Walker, G.; Dong, Y. Formulation and Delivery Technologies for mRNA Vaccines. Curr. Top. Microbiol. Immunol. 2022, 440, 71–110. DOI: 10.1007/82_2020_217 DOI: https://doi.org/10.1007/82_2020_217

63. Dowdy, S. Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? RNA 2023, 29(4), 396-401. DOI: 10.1261/rna.079507.122 DOI: https://doi.org/10.1261/rna.079507.122

64. Fang, E.; Liu, X.; Li, M.; Zhang, Z.; Song, L.; Zhu, B.; et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target. Ther. 2022, 7(94), Art. No: 94. DOI: 10.1038/s41392-022-00950-y DOI: https://doi.org/10.1038/s41392-022-00950-y

65. Chavda, V.; Jogi, G.; Dave, S.; Patel, B.; Vineela, Nalla. L.; Koradia, K. mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown! Vaccines 2023, 11(3), Art. No: 507. DOI: 10.3390/vaccines11030507 DOI: https://doi.org/10.3390/vaccines11030507

66. Varkouhi, A.; Scholte, M.; Storm, G.; Haisma, H. Endosomal escape pathway for delivery of biologicals. J. Control Rel. 2011, 151(3), 220-228. DOI: 10.1016/j.jconrel.2010.11.004 DOI: https://doi.org/10.1016/j.jconrel.2010.11.004

67. Schlich, M.; Palomba, R.; Costabile, G.; Shoshy, Mizrahy S.; Pannuzzo, M.; Peer, D.; et al. Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. Bioeng. Transl. Med. 2021, 6(2), Art. No: e10213. DOI: 10.1002/btm2.10213 DOI: https://doi.org/10.1002/btm2.10213

68. Paramasivam, P.; Franke, C.; Stoter, M.; Hoijer, A.; Stefano, Bartesaghi. S.; Sabirsh, A.; et al. Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale. J. Cell Biol. 2022, 221(2), Art. No: e202110137. DOI: 10.1083/jcb.202110137 DOI: https://doi.org/10.1083/jcb.202110137

69. Institute of Medicine (US) Board on Health Promotion and Disease Prevention. Immune Response to Vaccine Antigens, in: Vaccine Safety Forum: Summaries of Two Workshops. Washington (DC): National Academies Press (US) 1997. Available from: https://www.ncbi.nlm.nih.gov/books/NBK233000/

70. Al Fayez, N.; Nassar, M.; Alshehri, A.; Alnefaie, M.; Almughem, F.; Alshehri, B.; et al. Recent Advancement in mRNA Vaccine Development And Applications. Pharmaceutics 2023, 15(7), Art. No: 1972. DOI: 10.3390/pharmaceutics15071972 DOI: https://doi.org/10.3390/pharmaceutics15071972

71. Sijts, E.; Kloetzel, P. The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell. Mol. Life Sci. 2011, 68(9), 1491–1502. DOI: 10.1007/s00018-011-0657-y DOI: https://doi.org/10.1007/s00018-011-0657-y

72. Cruz, F.; Chan, A.; Rock, K.; Pathways of MHC I cross-presentation of exogenous antigens. Semin. Immunol. 2023, 66, Art. No: 101729. DOI: 10.1016/j.smim.2023.101729 DOI: https://doi.org/10.1016/j.smim.2023.101729

73. Vojdani, A.; Koksoy, S.; Vojdani, E.; Engelman, M.; Benzvi, M.; Lerner, A. Natural Killer Cells and Cytotoxic T Cells: Complementary Partners against Microorganisms and Cancer. Microorganisms 2024, 12(1), Art. No: 230. DOI: 10.3390/microorganisms12010230. DOI: https://doi.org/10.3390/microorganisms12010230

74. Bellavite, P.; Alessandra Ferraresi, A.; Isidoro, C. Immune Response and Molecular Mechanisms of Cardiovascular Adverse Effects of Spike Proteins from SARS-CoV-2 and mRNA Vaccines. Biomedicines 2023, 11(2), Art. No: 451. DOI: 10.3390/biomedicines11020451. DOI: https://doi.org/10.3390/biomedicines11020451

75. Gohda, E. Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms. J. Disaster. Res. 2022, 17(1), 7-20. DOI: 10.20965/jdr.2022.p0007 DOI: https://doi.org/10.20965/jdr.2022.p0007

76. Lee, J.; Woodruff, M.; Kim, E.; Nam, J. Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines. Exp. Mol. Med. 2023, 55(7), 1305-1313. DOI: 10.1038/s12276-023-00999-x DOI: https://doi.org/10.1038/s12276-023-00999-x

77. Lam, J.; Smith, F.; Baumgarth, N. B Cell Activation and Response Regulation During Viral Infections. Viral Immunol. 2020, 33(4), 294-306. DOI: 10.1089/vim.2019.0207 DOI: https://doi.org/10.1089/vim.2019.0207

78. Dai, L.; Gao, G. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 2021, 21, 73-82. DOI: 10.1038/s41577-020-00480-0 DOI: https://doi.org/10.1038/s41577-020-00480-0

79. Mancuso, R.; Agostini, S.; Citterio, L.; Chiarini, D.; Santangelo, M.; Clerici, M. Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines. Vaccines 2022, 10(10), Art. No: 1649. DOI: 10.3390/vaccines10101649 DOI: https://doi.org/10.3390/vaccines10101649

80. FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine. Action Follows Thorough Evaluation of Available Safety, Effectiveness, and Manufacturing Quality Information by FDA Career Scientists, Input from Independent Experts. Administration FaD; 2020. Available online: https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19 (accessed on 17-10-2024)

81. Sahin, U.; Muik, A.; Vogler, I.; Derhovanessian, E.; Kranz, L.; Vormehr, M.; et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 2021, 595, 572-577. DOI: 10.1038/s41586-021-03653-6. DOI: https://doi.org/10.1038/s41586-021-03653-6

82. FDA Approves First COVID-19 Vaccine. Approval Signifies Key Achievement for Public Health. Administration FaD; 2021. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine (accessed on17-10-2024)

83. FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age. Administration FaD; 2021. Available online: https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age (accessed on 17-10-2024) DOI: https://doi.org/10.47287/cen-09931-buscon1

84. Fernando, k.; Menon, S.; Jansen, k.; Naik, P.; Nucci, G.; Roberts, J.; et al. Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity. Drug Discov. Today 2022, 27(3), 697-704. DOI: 10.1016/j.drudis.2021.2.010 DOI: https://doi.org/10.1016/j.drudis.2021.12.010

85. Rohde, C.; Lindemann, C.; Giovanelli, M.; Sellers, R.; Diekmann, J.; Choudhary, S.; et al. Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines. Vaccines 2023, 11(2), Art. No: 417. DOI: 10.3390/vaccines11020417 DOI: https://doi.org/10.3390/vaccines11020417

86. Vogel, A.; Kanevsky, I.; Che, Y.; Swanson, K.; Muik, A.; Vormehr, M. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 2021, 592, 283-289. DOI: 10.1101/2020.09.08.280818. DOI: https://doi.org/10.1038/s41586-021-03275-y

87. Walsh, E.; Frenck, R.; Falsey, A.; Kitchin, N.; Absalon, J.; Gurtman, A.; et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med. 2020, 383, 2439-2450. DOI: 10.1056/NEJMoa2027906. DOI: https://doi.org/10.1056/NEJMoa2027906

88. Mulligan, M.; Lyke, K.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020, 586, 589-593. DOI: 10.1038/s41586-020-2639-4. DOI: https://doi.org/10.1038/s41586-020-2639-4

89. Polack, F.; Thomas, S.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603-2615. DOI: 10.1056/NEJMoa2034577. DOI: https://doi.org/10.1056/NEJMoa2034577

90. Kadalia, R.; Janagamac, R.; Perurud, S.; Malayalae, S. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. IJID. 2021, 106, 376–381. DOI: 10.1016/j.ijid.2021.04.047 DOI: https://doi.org/10.1016/j.ijid.2021.04.047

91. Thomas, S.; Moreira, E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N. Engl. J. Med. 2021, 385(10), 1761-1773. DOI: 10.1056/NEJMoa2110345 DOI: https://doi.org/10.1056/NEJMoa2110345

92. Gobbi, F.; Buonfrate, D.; Moro, L.; Rodari, P.; Piubelli, C.; Caldrer, S.; et al. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine In Subjects with Prior SARS-CoV-2 Infection. Viruses 2021, 13(3), Art. No: 422. DOI: 10.3390/v13030422 DOI: https://doi.org/10.3390/v13030422

93. Frenck, R.; Klein, N.; Kitchin, N.; Gurtman, A.; Absalon, J.; Lockhart, S.; et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N. Engl. J. Med. 2021, 385, 239-250. DOI: 10.1056/NEJMoa2107456 DOI: https://doi.org/10.1056/NEJMoa2107456

94. Walter, E.; Talaat, K.; Sabharwal, C.; Gurtman, A.; Lockhart, S.; Paulsen, G.; et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N. Engl. J. Med. 2022, 386, 35-46. DOI: 10.1056/NEJMoa2116298 DOI: https://doi.org/10.1056/NEJMoa2116298

95. Moreira, E.; Kitchin, N.; Xu, X.; Dychter, S.; Lockhart, S.; Gurtman, A.; et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N. Engl. J. Med. 2022, 386(20), 1910-1921. DOI: 10.1056/NEJMoa2200674 DOI: https://doi.org/10.1056/NEJMoa2200674

96. Thomas, S.; Perez, J.; Lockhart, S.; Hariharan, S.; Kitchin, N.; Bailey, R.; et al. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine 2022, 40, 1483-1492. DOI: 10.1016/j.vaccine.2021.12.046 DOI: https://doi.org/10.1016/j.vaccine.2021.12.046

97. Seekircher, L.; Bánki, Z.; Kimpel, J.; Rössler, A.; Schäfer, H.; Falkensammer, B.; et al. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial. Lancet Microb. 2023, 4(8), e612-e621. DOI: 10.1016/s2666-5247(23)00107-6 DOI: https://doi.org/10.1016/S2666-5247(23)00107-6

98. Clairon, Q.; Prague, M.; Planas, D.; Bruel, T.; Hocqueloux, L.; Prazuck, T.; et al. Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2. PloS Comput. Biol. 2023, 19(8), Art. No: e1011282. DOI: 10.1371/journal.pcbi.1011282 DOI: https://doi.org/10.1371/journal.pcbi.1011282

99. Fitz-Patrick, D.; Young, M.; Yacisin, K.; McElwee, K.; Belanger, T.; Belanger, K.; et al. Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old. Vaccine 2023, 41, 4190-4198. DOI: 10.1016/j.vaccine.2023.05.002. DOI: https://doi.org/10.1016/j.vaccine.2023.05.002

100. Chantasrisawad, N.; Techasaensiri, C.; Kosalarksa, P.; Phongsamart, W.; Tangsathapronpong, A.; Ampornpan, J.; et al. The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial. Int. J. Infect. Dis. 2023, 130, 52-59. DOI: 10.1016/j.ijid.2023.02.017 DOI: https://doi.org/10.1016/j.ijid.2023.02.017

101. Simões, E.; Klein, P.; Sabharwa, C.; Gurtman, A.; Kitchin, N.; Ukkonen, B.; et al. Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds. J. Pediatric. Infect. Dis. Soc. 2023, 12(4), 234-238. DOI: 10.1093/jpids/piad015 DOI: https://doi.org/10.1093/jpids/piad015

102. Radner, H.; Sieghart, D.; Jorda, A.; Fedrizzi, C.; Hasenöhrl, T.; Zdravkovic, A.; et al. Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers. Clin. Microbiol. Infect. 2022, 29(5), 635-641. DOI: 10.1016/j.cmi.2022.12.008 DOI: https://doi.org/10.1016/j.cmi.2022.12.008

103. Muñoz, F.; Sher, L.; Sabharwal, C.; Gurtman, A.; Xu, X.; Kitchin, N.; Lockhart, S.; et al. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. N. Engl. J. Med. 2023, 388(7), 621-634. DOI: 10.1056/NEJMoa2211031 DOI: https://doi.org/10.1056/NEJMoa2211031

104. Munro, A.; Feng, S.; Janani, L.; Cornelius, V.; Aley, P.; Babbage, G.; et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect. Dis. 2022, 22(8), 1131-1141. DOI: 10.1016/S1473-3099(22)00271-7 DOI: https://doi.org/10.1016/S1473-3099(22)00271-7

105. Bergman, P.; Blennow, O.; Hansson, L.; Mielke, S.; Nowak, P.; Chen, p.; et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMed. 2021, 74, Art. No: 103705. DOI: 10.1016/j.ebiom.2021.103705 DOI: https://doi.org/10.1016/j.ebiom.2021.103705

106. Usdan, L.; Patel, S.; Rodriguez, H.; Xu, X.; Lee, D.; Finn, D.; et al. A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds. Clin. Infect. Dis. 2024, 78(5), 1194-1203. DOI: 10.1093/cid/ciad718 DOI: https://doi.org/10.1093/cid/ciad718

BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety

Esraa Alkhalil

Bashar Jarad

Tala Saleh

Wafaa Aldarwish

Dr. Dima Joujeh

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Esraa Alkhalil

Bashar Jarad

Tala Saleh

Wafaa Aldarwish

Dr. Dima Joujeh